Effects of Shenmai Injection(参麦注射液)Combined with Meglumine Adenosine Cyclophosphate Injection on Cardiac Function and Peripheral Serum Levels of TNF-α,TGF-β1 and IFN-γ in Patients with Viral Myocarditis

Objective: To explore effects of Shenmai Injection(参麦注射液) combined with Meglumine Adenosine Cyclophosphate Injection on cardiac function and peripheral serum levels of tumor necrosis factor-α(TNF-α), transforming growth factor-β1(TGF-β1) and interferon-γ(IFN-γ) in patients with viral myocarditis.Methods: A total of 70 patients with viral myocarditis admitted in Cardiovascular Medicine Department of our hospital from June 2016 to June 2018 were selected and divided into a control group(treated with Meglumine Adenosine Cyclophosphate Injection) and an observation group(additionally treated with Shenmai Injection(参麦注射液) on the treatment basis of the control group) according to random number method, with 35 cases in each group.Before and after the treatment, cardiac functional indexes like cardiac index(CI), left ventricular ejection fraction(LVEF) and left ventricular shortening fraction(FS), serum levels of TNF-α, TGF-β1 and IFN-γ, clinical efficacy and adverse reactions occurred in the 2 groups were recorded and compared.Results: Therapeutic effective rate in the observation group was 88.57%, higher than 68.57% in the control group(P < 0.05).After the treatment, cardiac functional indexes like CI, LVEF and FS were higher than those in the control group(P < 0.05).After the treatment, the serum expression levels of TNF-α and TGF-β1 were lower than those in the control group(P < 0.05), while the serum expression level of IFN-γ was higher than that in the control group(P < 0.05).There was no statistically significant difference in the adverse reaction rates between the 2 groups(P > 0.05).Conclusion: The treatment of patients with viral myocarditis by Shenmai Injection(参麦注射液) combined with Meglumine Adenosine Cyclophosphate Injection is more effective, reducing inflammation and restoring cardiac function.

Oral administration of dibutyryl adenosine cyclophosphate improved growth performance in weaning piglets by enhancing lipid fatty acids metabolism

Dibutyryl adenosine cyclophosphate(dbc AMP-Ca), an analog of cyclic adenosine monophosphate(c AMP), plays greater roles in regulating physiological activities and energy metabolism than c AMP. The aim of this study was to investigate the effect of oral administration of dbc AMP-Ca on growth performance and fatty acids metabolism in weaning piglets. A total of 14 early weaning piglets(7 ± 1 d of age,3.31 ± 0.09 kg, Landrace ? Large White ? Duroc) were randomly divided into 2 groups: control group and dbc AMP-Ca group, and the piglets received 7 m L of 0.9% Na Cl or 1.5 mg dbc AMP-Ca dissolved in 7 m L of 0.9% Na Cl per day for 10 d, respectively. The results showed that the average daily gain(ADG)increased by 109.17%(P < 0.05) in the dbc AMP-Ca group compared with the control group. Besides,dbc AMP-Ca significantly decreased blood high density lipoprotein cholesterol(HDLC) concentration(P < 0.05) and significantly increased blood low density lipoprotein cholesterol(LDLC) concentration(P < 0.05) compared with the control group. Further, liver C18:2 n6 t content significantly increased in dbc AMP-Ca group(P < 0.05) compared with the control group. With the increase of C18:2 n6 t content,the m RNA expression levels of peroxisome proliferator-activated receptor a(PPARa) and hormone sensitive glycerol three lipase(HSL), of which genes are related to lipid metabolism, were also significantly increased(P < 0.05 or P < 0.01). All of the results indicated that dbc AMP-Ca improved the ADG, which was probably done by regulating fatty acids metabolism in the liver of weaning piglets.